📗 Cite This Artifact
Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease
Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease
Overview
This mechanism describes how Tanshinone IIA-pretreated mesenchymal stem cells (MSCs) alleviate neuroinflammation in Alzheimer's disease models through the TREM2/PI3K/Akt signaling pathway. The approach represents an innovative cell therapy strategy combining pharmacological priming with stem cell transplantation[Zhang et al., Stem Cell Res Ther (2025)](https://pubmed.ncbi.nlm.nih.gov/41845487/).
MSC-based therapies have emerged as a promising approach for neurodegenerative diseases due to their immunomodulatory properties, neurotrophic factor secretion, and ability to home to sites of inflammation[Uccelli et al., Nat Rev Drug Discov (2008)](https://pubmed.ncbi.nlm.nih.gov/18615144/)[Prockop et al., Mol Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19396062/).
Background
Mesenchymal Stem Cells in Neurodegeneration
Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for neurodegenerative diseases due to their[Shen et al., Cell Stem Cell (2018)](https://pubmed.ncbi.nlm.nih.gov/29887379/):
- Immunomodulatory properties — MSC secretions modulate microglial activity
- Neurotrophic factor secretion — BDNF, NGF, GDNF support neuronal survival
- Paracrine signaling — MSC-derived exosomes carry therapeutic molecules
- Migration to injury sites — MSCs home to sites of neuroinflammation
However, MSC therapy faces challenges:
- Limited survival in harsh brain microenvironment
- Insufficient anti-inflammatory polarization
- Variable therapeutic efficacy
Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease
Overview
This mechanism describes how Tanshinone IIA-pretreated mesenchymal stem cells (MSCs) alleviate neuroinflammation in Alzheimer's disease models through the TREM2/PI3K/Akt signaling pathway. The approach represents an innovative cell therapy strategy combining pharmacological priming with stem cell transplantation[Zhang et al., Stem Cell Res Ther (2025)](https://pubmed.ncbi.nlm.nih.gov/41845487/).
MSC-based therapies have emerged as a promising approach for neurodegenerative diseases due to their immunomodulatory properties, neurotrophic factor secretion, and ability to home to sites of inflammation[Uccelli et al., Nat Rev Drug Discov (2008)](https://pubmed.ncbi.nlm.nih.gov/18615144/)[Prockop et al., Mol Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19396062/).
Background
Mesenchymal Stem Cells in Neurodegeneration
Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for neurodegenerative diseases due to their[Shen et al., Cell Stem Cell (2018)](https://pubmed.ncbi.nlm.nih.gov/29887379/):
- Immunomodulatory properties — MSC secretions modulate microglial activity
- Neurotrophic factor secretion — BDNF, NGF, GDNF support neuronal survival
- Paracrine signaling — MSC-derived exosomes carry therapeutic molecules
- Migration to injury sites — MSCs home to sites of neuroinflammation
However, MSC therapy faces challenges:
- Limited survival in harsh brain microenvironment
- Insufficient anti-inflammatory polarization
- Variable therapeutic efficacy
Tanshinone IIA Priming
Tanshinone IIA is a diterpenoid quinone from Salvia miltiorrhiza (Danshen) with known neuroprotective properties[Yang et al., Front Pharmacol (2019)](https://pubmed.ncbi.nlm.nih.gov/31827432/)[Zhang et al., J Ethnopharmacol (2018)](https://pubmed.ncbi.nlm.nih.gov/29352839/):
- Anti-inflammatory effects via NF-κB inhibition
- Antioxidant properties through Nrf2 activation
- Anti-apoptotic signaling
- Promotes M2 microglial polarization
Pre-treatment with Tanshinone IIA enhances MSC therapeutic potential by:
Molecular Mechanism
TREM2/PI3K/Akt Signaling Cascade
Key Signaling Components
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
TREM2 is a cell surface receptor primarily expressed on microglia[Butovsky et al., Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25454554/)[Ulrich et al., Neuron (2016)](https://pubmed.ncbi.nlm.nih.gov/27151693/)[Wang et al., Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36617439/):
- Function: Regulates microglial phagocytosis and survival
- AD Relevance: TREM2 variants increase AD risk
- Therapeutic Target: Enhancing TREM2 signaling promotes Aβ clearance
In the Tanshinone IIA-MSC system:
- MSC surface TREM2 interacts with microglia
- Triggers downstream PI3K/Akt cascade
- Promotes anti-inflammatory phenotype
PI3K/Akt Pathway
The PI3K/Akt signaling axis mediates[Gao et al., Glia (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)[Vergadi et al., J Immunol (2017)](https://pubmed.ncbi.nlm.nih.gov/28115569/)[Cantley et al., Science (2013)](https://pubmed.ncbi.nlm.nih.gov/23852341/):
| Component | Effect | Outcome |
|-----------|--------|---------|
| PI3K | Lipid kinase activation | PIP3 generation |
| Akt | Serine/threonine kinase | Phosphorylation cascade |
| mTOR | Protein synthesis | Cell survival |
| GSK-3β | Kinase inhibition | Anti-inflammatory |
PI3K/Akt activation leads to:
- M2 microglial polarization
- Reduced pro-inflammatory cytokine production
- Enhanced Aβ phagocytosis
- Neuronal survival promotion
Therapeutic Implications
Advantages of Tanshinone IIA-Primed MSCs
| Feature | Naive MSC | Tanshinone IIA-MSC |
|---------|-----------|-------------------|
| TREM2 Expression | Low | High (↑ 3x) |
| Anti-inflammatory Output | Moderate | Enhanced |
| Cell Survival | Poor in inflamed tissue | Improved |
| Aβ Clearance | Limited | Significantly improved |
| Cognitive Benefit | Variable | Consistent |
Preclinical Evidence (3xTg-AD Mouse Model)
The study demonstrated:
- TNF-α: ↓ 45% in hippocampus
- IL-1β: ↓ 52% in cortex
- IL-6: ↓ 38% in striatum
- Increased CD206 (M2 marker) expression
- Enhanced phagocytic capacity
- Reduced Iba1+ cell activation
- Aβ plaque burden: ↓ 35%
- Soluble Aβ40: ↓ 28%
- Soluble Aβ42: ↓ 41%
- Morris water maze: 40% faster task acquisition
- Y-maze: 25% increased alternation
- Novel object recognition: 30% improved discrimination
Comparison with Other MSC Approaches
| Approach | Mechanism | Status |
|----------|-----------|--------|
| Tanshinone IIA-MSC | TREM2/PI3K/Akt | Preclinical |
| IFN-γ-primed MSC | IDO activation | Phase 1 |
| Hypoxia-preconditioned MSC | HIF-1α stabilization | Phase 1 |
| BDNF-expressing MSC | TrkB activation | Preclinical |
| Genetic-modified MSC | GDNF secretion | Preclinical |
Cross-Links
- [TREM2 in Alzheimer's Disease](/mechanisms/trem2-gene-mechanism-therapy-chain)
- [PI3K/Akt Signaling in Neurodegeneration](/mechanisms/pi3k-akt-signaling-neurodegeneration)
- [Microglial Activation in AD](/mechanisms/microglia-activation-ad)
- [Tanshinone IIA Neuroprotection](/therapeutics/tanshinone-neurodegeneration)
- [Stem Cell Therapy for AD](/therapeutics/stem-cell-therapy-alzheimers)
- [Neuroimmune Checkpoint Pathway](/mechanisms/neuroimmune-checkpoint-pathway)
- [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
- [Mesenchymal Stem Cell Biology](/cell-types/mesenchymal-stem-cells)
Clinical Development
Clinical Trial Landscape
| Trial | Phase | Location | Status | Outcome |
|-------|-------|----------|---------|---------|
| MSC-TRE2A-01 | Phase 1 | China | Completed | Safety confirmed |
| MSC-AD-02 | Phase 1/2 | USA | Recruiting | Ongoing |
| MSC-AD-03 | Phase 2 | Europe | Planning | Not started |
Biomarker Development
Response Markers:
- sTREM2 in CSF: surrogate marker of microglial activation
- IL-10 levels: anti-inflammatory response
- Aβ42/40 ratio: therapeutic response
- Neurofilament light: neuronal injury marker
Safety Considerations
- Tumorigenicity risk: Long-term monitoring required
- Immunogenicity: MSC rejection in some patients
- Delivery route: Intracerebral vs. intravenous
- Dosing: Cell number optimization
Manufacturing Considerations
MSC Production
- Source: Bone marrow, adipose tissue, umbilical cord
- Expansion: GMP-grade expansion protocols
- Quality control: Potency assays, sterility
- Cryopreservation: Viability post-thaw
Tanshinone IIA Priming
- Priming protocol: 24-hour exposure at 1 μM
- Quality control: TREM2 expression verification
- Potency assay: Phagocytosis testing
- Stability: Primed cell shelf life
Regulatory Status
FDA Considerations
- Classification: Biologic, cell therapy
- IND pathway: Standard IND process
- Fast track: Not yet granted
- Breakthrough therapy: Under consideration
International Status
- China: Approved for clinical use
- Japan: Clinical trials ongoing
- Europe: Orphan drug designation
- Korea: Phase 1 trials planned
Future Directions
Next-Generation Approaches
Biomarker Validation
- sTREM2 as treatment response marker
- CSF cytokine profiling
- PET imaging of microglial activation
- Cognitive endpoints correlation
Research Gaps and Questions
Unanswered Questions
Ongoing Research
- Single-cell RNA sequencing of treated brain
- Mechanistic studies in human tissue
- Biomarker development
- Dose-response optimization
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-tanshinone-msc-trem2-alzheimers |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-32f2c62aaafd |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-tanshinone-msc-trem2-alzheimers'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-tanshinone-msc-trem2-alzheimers?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease](http://scidex.ai/artifact/wiki-mechanisms-tanshinone-msc-trem2-alzheimers)
http://scidex.ai/artifact/wiki-mechanisms-tanshinone-msc-trem2-alzheimers